Epidemiology and treatment of hepatitis C genotypes 5 and 6

Khalid Al Naamani MD FRCPC1, Siham Al Sinani MD FRCPC2, Marc Deschênes MD FRCPC3

Chronic hepatitis C infection is a major global health problem. The WHO estimates the number of infected people worldwide to be approximately 170 million. The estimated number of hepatitis C virus (HCV)-infected people in Canada is approximately 250,000, with approximately 5000 Canadians newly infected each year. Based on the identification of genomic differences, HCV has been classified into six genotypes; genotype may influence the outcome of antiviral therapy. HCV genotypes 1, 2 and 3 are widely distributed throughout the world and have been the focus of the majority of epidemiological, natural course and treatment studies. Although HCV genotypes 5 and 6 are prevalent in certain geographical areas, they are studied less extensively. HCV genotypes 5 and 6 are uncommon in Canada and account for less than 5% of HCV-infected Canadians. However, immigration and travel can alter the epidemiology of these uncommon genotypes. The present article reviews and summarizes the available data regarding the epidemiology and treatment of HCV genotypes 5 and 6. Genotype 5 is endemic in the northern part of South Africa while genotype 6 is reported primarily in Asia. Available data show that 48 weeks of treatment with a combination of pegylated interferon and ribavirin lead to a higher sustained virological response compared with HCV genotypes 1 and 4. None of the approved direct-acting antiviral agents is currently recommended for the treatment of HCV genotypes 5 or 6.

Key Words: Chronic; Hepatitis C; Genotype

HCV GENOTYPE 5

Epidemiology

HCV genotype 5 has only one subtype: 5a. It is found mainly in South Africa, where it accounts for 40% of HCV infections (8). The reported prevalences of HCV genotype 5 in different parts of the world are shown in Table 1. Pockets of HCV genotype 5 can be found worldwide. However, with the exception of South Africa, it is considered to comprise only a minor proportion of the HCV population. Nucleotide sequence analysis of the NS5B region was performed on 8479 HCV-positive patients from Quebec (15). Fifty-three patients had HCV genotype 5, accounting for only 0.64% of cases. Most of these patients were females and were older than patients infected by other genotypes (15). Most of the studies describing HCV genotype 5 prevalence show no contact between endemic areas and the northern part of South Africa.

There are limited data available on the clinical, biological and pathological features of HCV genotype 5 infection. Most of the studies describing patients infected with HCV genotype 5 involve a small sample size, and most patients are women 50 years of age and older (10,12,16), who tend to have a high viral load (>10^6 copies/mL) (17). The common identifiable transmission modes are iatrogenic, blood transfusion and intravenous drug use. Approximately 30% of patients have cirrhosis at the time of presentation (17). One of the most
Hepatitis C genotypes 5 and 6

**TABLE 1**
Summary of hepatitis C virus genotype 5 prevalence

<table>
<thead>
<tr>
<th>Author (reference)</th>
<th>Country</th>
<th>Prevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smuts and Kannemeyer</td>
<td>South Africa (northern)</td>
<td>39.2</td>
</tr>
<tr>
<td>Payan et al (9)</td>
<td>France (central)</td>
<td>14.2</td>
</tr>
<tr>
<td>Antaki et al (10)</td>
<td>Syria</td>
<td>10</td>
</tr>
<tr>
<td>Shobokshi et al (11)</td>
<td>Saudi Arabia</td>
<td>1</td>
</tr>
<tr>
<td>Antaki et al (12)</td>
<td>Canada (Montreal, Quebec)</td>
<td>5</td>
</tr>
<tr>
<td>D’Heygere et al (13)</td>
<td>Belgium</td>
<td>4.2</td>
</tr>
<tr>
<td>Jover et al (14)</td>
<td>Spain (southeast)</td>
<td>10.3</td>
</tr>
</tbody>
</table>

**TABLE 2**
Summary of studies describing treatment of hepatitis C virus genotype 5

<table>
<thead>
<tr>
<th>Author (Reference)</th>
<th>Study design</th>
<th>Patients, n</th>
<th>Treatment</th>
<th>Duration, weeks</th>
<th>SVR, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonny et al (20)</td>
<td>Retrospective</td>
<td>44</td>
<td>IFN monotherapy</td>
<td>48</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peg-IFN + ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legrand-Abravanel et al (21)</td>
<td>Case control</td>
<td>3</td>
<td>IFN-alpha + ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peg-IFN + ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonny et al (22)</td>
<td>Retrospective</td>
<td>28</td>
<td>IFN + ribavirin</td>
<td>48</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peg-IFN + ribavirin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antaki et al (23)</td>
<td>Retrospective</td>
<td>17</td>
<td>IFN + ribavirin</td>
<td>24–48</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peg-IFN + ribavirin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| IFN Interferon; Peg-IFN Pegylated IFN; SVR Sustained virological response

important factors for the development of advanced liver disease is the duration of infection. Few studies have compared the prevalence of hepatocellular carcinoma (HCC) among different HCV genotypes; however, genotype does not appear to influence the development of HCV-associated HCC (18,19).

**Treatment**

Data regarding treatment for HCV genotype 5 is scant. This is mainly due to the low prevalence of HCV genotype 5 worldwide. Due to the lack of data, HCV genotype 5 is generally regarded to have a low response rate to treatment with interferon (IFN)-alpha and ribavirin combination therapy, and treatment intensity as well as duration is similar to that for HCV genotype 1. Table 2 summarizes the studies describing treatment of HCV genotype 5.

One of the first studies describing the treatment of HCV genotype 5 was a retrospective study from France by Bonny et al (20). Patients were treated with standard IFN monotherapy, or a combination of standard IFN and ribavirin for 48 weeks. The sustained virological response (SVR) for standard IFN alone was lower than that for combination standard IFN and ribavirin (31% versus 71% [P<0.05]). The SVR after 48 weeks of treatment was comparable with that of HCV genotypes 2 and 3. In a case control study by Legrand et al (21), 12 patients with HCV genotype 5 were treated with standard IFN plus ribavirin (three patients) or pegylated IFN (peg-IFN) with ribavirin (nine patients) for 48 weeks. The study reported that all patients had absence of detectable virus at 24 weeks of treatment and at the end of treatment (48 weeks). The SVR in patients infected with HCV genotype 5 was better than that in patients infected with HCV genotype 1 (63.6% versus 22.7%, respectively [P<0.05]) despite high viral load in patients with HCV genotype 5 and was comparable with that in patients infected with HCV genotypes 2 or 3 (66.6%). A retrospective study with a larger sample size (n=87) with HCV genotype 5 was reported by Bonny et al (22). Twenty-eight patients were treated for 48 weeks with standard IFN (3 million units [MU] three times per week) plus ribavirin (800 mg/day to 1200 mg/day) and 59 patients were treated for 48 weeks with peg-IFN alpha-2b (1.5 μg/kg/week) plus ribavirin (800 mg/kg to 1200 mg/kg). The overall SVR rate among patients with HCV genotype 5 was 60% (52 of 87). Thirty per cent (26 of 87) experienced relapse after the end of treatment response (ETR), they were older than those who achieved SVR and received lower doses of ribavirin. Ten per cent (nine of 87) were nonresponders and had the same baseline characteristics as the relapsers. There was no statistically significant difference between the SVR in patients treated with peg-IFN and those treated with standard IFN. Antaki et al (23) conducted a retrospective study in which 26 patients with HCV genotype 5 were treated with ribavirin 1000 mg/day to 1200 mg/day plus either standard IFN or peg-IFN for 24 or 48 weeks. Fifty-four per cent demonstrated an SVR (47% with standard IFN and 67% with peg-IFN [P=0.43]). Younger patients with low viral load and milder histology had better results. There was no statistically significant difference with respect to SVR between those who were treated for 24 weeks compared with 48 weeks. This was the first study describing high SVR with shorter duration of treatment. However, caution must be exercised due to the small sample size, nonstandardized treatment and study design.

In summary, the above studies demonstrated that treatment of HCV genotype 5 with a combination of peg-IFN and ribavirin for 48 weeks resulted in high SVR (60%), comparable with that of genotypes 2 and 3. Because treatment duration has not yet been established, large randomized clinical studies are required to determine the optimum duration of treatment. The available data to date suggest that treatment of HCV genotype 5 should consist of a combination of peg-IFN and ribavirin for 48 weeks. Response-guided therapy has not been studied in this patient population.

**HCV GENOTYPE 6**

**Epidemiology**

Most reports regarding HCV genotype 6 are from Asian countries including Hong Kong, Thailand, Indonesia, China, Vietnam, Myanmar and Korea (24-32) (Table 3). There are few reports of HCV genotype 6 in Australia, Canada and the United States, where most of these patients were immigrants from endemic areas. Murphy et al (15) reported that 146 of 8479 HCV-positive patient samples from Quebec were infected with genotype 6, accounting for 1.8% of cases. The most prevalent subtype of genotype 6 was 6e (40.4%). With the exception of three patients, all patients infected with HCV genotype 6 were of Asian origin. Spread of genotype 6 is expected to rise due to increasing immigration from endemic areas. Novel HCV genotypes 7, 8 and 9, found mainly in Vietnam, as well as genotype 11 found in Indonesia, are closely related to genotype 6 and have been reclassified as subtypes of genotype 6 (33). HCV genotype 6 has 21 subtypes assigned the letters a to u. Four new subtypes, 6r to 6u, were discovered recently. With the exception of the 6a subtype, most of the other subtypes are very rare, which could be partly due to incomplete sampling or low frequency. Data regarding risk factors for HCV genotype 6 are lacking. Similar to most HCV genotypes, unsafe therapeutic injections, intravenous drug use and blood transfusion are probable modes of transmission of HCV genotype 6 (12). Available data regarding clinical manifestations are scant. In one study (34), there were no differences found between HCV genotype 1 and 6 in liver biochemistry, titres, cirrhosis and risk for HCC.

**Treatment**

Most of the available data regarding treatment for HCV genotype 6 are based mainly on a few small nonrandomized trials. However, recently, two large randomized trials investigating the response rate to a combination of

Can J Gastroenterol Vol 27 No 1 January 2013 e9
Forty patients received ribavirin (1 g daily for patients weighing ≤75 kg and 1.2 g daily if weighing >75 kg). Patients with genotypes 1 and 6 received either an induction dose of standard IFN 5 MU daily for eight weeks followed by 3 MU three times weekly for 44 weeks or a dose of 3 MU three times weekly for 52 weeks. The authors reported an SVR of 83% in patients treated with standard IFN with ribavirin. Hui et al (36) prospectively compared the effect of IFN and ribavirin combination therapy in HCV genotypes 1 and 6. Of the 40 patients included, 16 had genotype 6 and 24 had genotype 1. Patients received standard IFN 5 MU three times weekly plus oral ribavirin 1.0 g/day in two divided doses if weighing ≤75 kg or 1.2 g/day for those weighing >75 kg. Patients with genotypes 1 and 6 received either an induction dose of standard IFN 5 MU daily for eight weeks followed by 3 MU three times weekly for 44 weeks or a dose of 3 MU three times weekly for 52 weeks. The authors reported an SVR of 83% in patients treated with standard IFN with ribavirin. Hui et al (36) prospectively compared the effect of IFN and ribavirin combination therapy in HCV genotypes 1 and 6. Of the 40 patients included, 16 had genotype 6 and 24 had genotype 1. Patients received standard IFN 5 MU three times weekly plus oral ribavirin 1.0 g/day in two divided doses if weighing ≤75 kg or 1.2 g/day if weighing >75 kg for 12 months. An SVR was achieved in 60 (62.5%) patients with genotype 6 and in seven (29.2%) patients with genotype 1. The same study demonstrated regression in fibrosis stage in four (25%) patients with genotype 6 and one (6.3%) patient with genotype 1 (P=0.2). Another retrospective study by Nguyen et al (37), in which 66 treatment-naive Asian-American patients with genotype 6 received either 24 weeks of standard IFN and ribavirin (31 patients), or peg-IFN and ribavirin (24 patients), or 48 weeks of peg-IFN and ribavirin (12 patients), demonstrated no significant difference in SVR after 24 weeks of treatment between the group receiving standard IFN and ribavirin compared with the group treated with peg-IFN and ribavirin (51.6% versus 39% [P=0.363]). However, the SVR in 12 patients treated with 48 weeks of peg-IFN and ribavirin was significantly higher than that in those treated with peg-IFN and ribavirin for 24 weeks (75% versus 39% [P=0.044]). The off-treatment relapse rate was 35% for the 24-week group compared with 17% for the 48-week group. A retrospective study by Fung et al (38) included 42 patients with HCV who were naïve to IFN treatment. Twenty-one patients infected with HCV genotype 1 were compared with 21 patients infected with HCV genotype 6. Both groups were treated with a combination of ribavirin and peg-IFN for 12 months. Treatment was stopped prematurely in six patients due to side effects. The study demonstrated that there was a significant difference in SVR (86% for genotype 6 versus 52% for genotype 1 [P=0.019]).

A larger multicentre, open-label randomized controlled study by Lam et al (39) involving 60 patients randomly assigned to peg-IFN with ribavirin for either 24 weeks (27 patients) or 48 weeks (33 patients) showed a high SVR in both groups (70% in the 24-week group and 79% in the 48-week group [P=0.451]). Patients treated for 48 weeks required more erythropoietin for anemia compared with patients treated for 24 weeks. The SVR was similar to randomized controlled trials involving an HCV genotype 1 in an Asian population. The authors suggested that combination therapy with peg-IFN alpha-2a and ribavirin for 24 weeks for HCV genotype 6 would be acceptable for patients who cannot tolerate 48 weeks of therapy. There are no reported studies investigating the response rate among different subtypes of genotype 6.

A pilot study evaluated treatment response on the basis of rapid virological response of HCV genotype 6 compared with genotypes 1 and 3. An SVR was achieved in 62.5%, 81.3% and 76.5% of patients with genotypes 1, 3 and 6, respectively. The SVR rate in patients with genotype 6 who underwent response-guided therapy was 88% (40). A recent, large open-label randomized trial from Vietnam involved 105 HCV genotype 6-infected patients who were randomly assigned to either 48 weeks (70 patients) or 24 weeks (35 patients) of peg-IFN alpha-2a and ribavirin therapy. Ninety-two patients completed the study (63 in the 48-week and 29 in the 24-week group). There was no statistical difference between the SVR in the two groups (71% for the 48-week group versus 60% for the 24-week group [P=0.24]) (41). These studies demonstrated that 48 weeks of treatment of HCV genotype 6 using a combination of peg-IFN and ribavirin resulted in a higher SVR compared with that of genotype 1 and approached the SVR reported for genotypes 2 and 3. The two recent randomized trials (39,41) revealed that 24 weeks of peg-IFN and ribavirin treatment resulted in SVRs comparable with 48 weeks of treatment. Reduced treatment time can be used in patients intolerant to treatment and those who achieve rapid virological response. Larger studies are required to determine the noninferiority of shorter-duration therapy before the recommendation of 24 weeks of therapy.

**INTERLEUKIN-28B POLYMORPHISM**

Recent genome-wide association studies revealed that host genetic variation is associated with hepatitis C treatment response as well as spontaneous clearance of the virus. Different single-nucleotide polymorphisms in the interleukin (IL)-28B gene in chromosome 19 coding for type III IFN-lambda had been found to be associated with HCV treatment response (42-44). Allele frequencies differ among ethnic groups, and this may explain the observed differences in response rates among Caucasians, African Americans and Asians. Studies have reported high response rates in the Asian population (35,45). High response rates in Asian patients with HCV genotype 6 could, in part, be due to IL-28 B polymorphism. However, none of the studies on the treatment of HCV genotype 5 and 6 examined the IL-28 B polymorphism as a response predictor.

**DIRECT-ACTING ANTIVIRAL AGENTS**

A better understanding of the viral cycle has led to the development of direct-acting antiviral agents (DAA). Two DAA, telaprevir and boceprevir – oral protease inhibitors targeting the NS3/NS4A region of the virus genome – have been approved in combination with peg-IFN and ribavirin in the treatment of HCV genotype 1 (46,47). Because the structure of the NS3/4A protease is different among HCV genotypes, protease inhibitors have different antiviral efficacy for different genotypes. The two approved HCV genotype 1 protease inhibitors boceprevir and telaprevir are not approved for HCV genotypes 5 and 6; therefore, peg-IFN and ribavirin currently remain the treatment of choice for both genotypes. Development of wider spectrum DAA, such as NSSA or entry inhibitors, may lead to other agents that could be used to treat patients with HCV genotypes 5 and 6.

**SUMMARY**

HCV genotypes 5 and 6 are uncommon in Canada and are endemic in the northern part of South Africa (genotype 5) and in certain parts of Asia (genotype 6). Due to the impact of globalization, the epidemiology of these uncommon genotypes is expected to change. Response of HCV genotypes 5 and 6 to 48 weeks of treatment with combination INF and ribavirin is better than that for genotypes 1 and 4. Until additional data are available, the recommended duration of treatment is 48 weeks. None of the new DAA are approved for the treatment of HCV genotypes 5 or 6.

Table 4: Summary of studies describing treatment of hepatitis C genotype 6

<table>
<thead>
<tr>
<th>Author (Reference)</th>
<th>Study design</th>
<th>Patients, n</th>
<th>Treatment Duration</th>
<th>SVR, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dev et al (35)</td>
<td>Prospective</td>
<td>40</td>
<td>IFN + ribavirin</td>
<td>52 weeks</td>
</tr>
<tr>
<td>Hui et al (36)</td>
<td>Prospective</td>
<td>16</td>
<td>IFN + ribavirin</td>
<td>12 months</td>
</tr>
<tr>
<td>Nugyen et al (37)</td>
<td>Retrospective</td>
<td>31</td>
<td>IFN + ribavirin, or</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Fung et al (38)</td>
<td>Retrospective</td>
<td>21</td>
<td>Peg-IFN + ribavirin</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Lam et al (39)</td>
<td>Open-label</td>
<td>27</td>
<td>Peg-IFN + ribavirin</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Tangkijvanich et al (40)</td>
<td>Pilot RCT</td>
<td>25</td>
<td>Peg-IFN + ribavirin</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Thu Thuy et al (41)</td>
<td>Open-label</td>
<td>70</td>
<td>Peg-IFN + ribavirin</td>
<td>48 weeks</td>
</tr>
<tr>
<td></td>
<td>RCT</td>
<td>35</td>
<td>Peg-IFN + ribavirin</td>
<td>24 weeks</td>
</tr>
</tbody>
</table>

IFN: Interferon; Peg-IFN: Pegylated IFN; RCT: Randomized controlled trial; RVR+: Rapid virological response positive or negative; SVR: Sustained virological response.
REFERENCES